Particle.news
Download on the App Store
9 ARTICLES
·
2w ago

Sanofi Seals $9.1 Billion Purchase of Blueprint Medicines

The addition of approved, late-stage immunology therapies triggers milestone-linked contingent value rights for Blueprint shareholders.

Image
French drugmaker Sanofi has ramped up research and development spending in recent years, prompting the company to abandon its long-term profit margin targets two years ago.
Image
Sanofi will pay $129 per share in cash, the companies said in a statement Monday.

Overview

  • Sanofi will acquire Blueprint for $129 per share in cash, valuing the deal at approximately $9.1 billion.
  • Blueprint shareholders will receive one non-tradeable contingent value right that could yield up to $6 per share upon the achievement of development and regulatory milestones.
  • The transaction value rises to roughly $9.5 billion on a fully diluted basis, including potential CVR payouts.
  • The acquisition adds Ayvakit/Ayvakyt, approved for systemic mastocytosis, as well as the next-generation drug elenestinib and the broad-spectrum KIT inhibitor BLU-808 to Sanofi’s immunology portfolio.
  • Sanofi expects to complete the takeover in the third quarter of 2025 as part of its strategy to become a leading company in rare immunological disease treatments.